Abstract
Background: Pharmacokinetics (PK), pharmacodynamics and optimal dosing of vancomycin in obese children is not known. Higher trough levels of vancomycin may improve outcomes. This prospective study evaluated the appropriateness of twice-daily regimen for the adherence to guidelines, among obese and non obese children.
Methods: Children receiving vancomycin, (20 mg/kg BID) were included. Patients were divided into 3 groups. Adequacy was defined as trough level ≥ 10mg/L and AUC/MIC > 400. An alternative-dosing regimen was calculated based on individual PK parameters.
Results: Seventy-seven pairs (trough, peak) were taken from 51 children. Mean trough level was 3.36±2.58, only 3% fell in therapeutic range, no statistical difference was observed between obese, normal weight or underweight groups. One child had an AUC/MIC > 400. All children recovered.
Conclusion: PK properties of all weight groups were similar. More frequent and higher doses are needed to achieve the goals of current guidelines.
Keywords: Guidelines, obesity, pediatric dosing, pharmacokinetics, trough levels, vancomycin, antimicrobials, antifungals, invasive, bacterial meningitis
Current Drug Safety
Title:Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Volume: 7 Issue: 5
Author(s): Laila Nassar, Salim Hadad, Aharon Gefen, Yael Shachor-Meyouhas, Tatiana Mashiach, Norberto Krivoy and Imad Kassis
Affiliation:
Keywords: Guidelines, obesity, pediatric dosing, pharmacokinetics, trough levels, vancomycin, antimicrobials, antifungals, invasive, bacterial meningitis
Abstract: Background: Pharmacokinetics (PK), pharmacodynamics and optimal dosing of vancomycin in obese children is not known. Higher trough levels of vancomycin may improve outcomes. This prospective study evaluated the appropriateness of twice-daily regimen for the adherence to guidelines, among obese and non obese children.
Methods: Children receiving vancomycin, (20 mg/kg BID) were included. Patients were divided into 3 groups. Adequacy was defined as trough level ≥ 10mg/L and AUC/MIC > 400. An alternative-dosing regimen was calculated based on individual PK parameters.
Results: Seventy-seven pairs (trough, peak) were taken from 51 children. Mean trough level was 3.36±2.58, only 3% fell in therapeutic range, no statistical difference was observed between obese, normal weight or underweight groups. One child had an AUC/MIC > 400. All children recovered.
Conclusion: PK properties of all weight groups were similar. More frequent and higher doses are needed to achieve the goals of current guidelines.
Export Options
About this article
Cite this article as:
Nassar Laila, Hadad Salim, Gefen Aharon, Shachor-Meyouhas Yael, Mashiach Tatiana, Krivoy Norberto and Kassis Imad, Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050009
DOI https://dx.doi.org/10.2174/1574886311207050009 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews The Role of 18F-FDG-PET/CT in Infectious Endocarditis and Cardiac Device Infection
Current Molecular Imaging (Discontinued) A Review of the Carbapenems in Clinical Use and Clinical Trials
Recent Patents on Anti-Infective Drug Discovery Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology MRSA Infections: From Classical Treatment to Suicide Drugs
Current Medicinal Chemistry Mycobacterium fortuitum Complex Skin Infection in a Healthy Adolescent
Infectious Disorders - Drug Targets Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design A Brief Overview of Antimicrobial Peptides Containing Unnatural Amino Acids and Ligand-Based Approaches for Peptide Ligands
Current Topics in Medicinal Chemistry Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Current Respiratory Medicine Reviews Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Preparation, Crystallization and Preliminary X-Ray Analysis of Threonine Synthase from Streptococcus mutans
Protein & Peptide Letters Perioperative Management of Patients with Down Syndrome
Current Pediatric Reviews Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery